UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2026
Opus Genetics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
001-34079
|
11-3516358
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
8 Davis Drive
Durham, NC
|
|
27713
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
| |
|
|
(984) 884-6030
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.0001 par value per share
|
IRD
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 |
Regulation FD Disclosure.
|
As previously announced, management of Opus Genetics, Inc., a Delaware corporation (the “Company”), will be delivering a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 8:15 a.m. Pacific Time. A live webcast of the presentation will be accessible
through the investor relations section of the Company’s website. The presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference. The Company has also made the presentation available to investors on the “Overview” section
of the Company’s website at https://ir.opusgtx.com.
The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by
reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing. The Company
undertakes no obligation to update, supplement, or amend the materials attached hereto as Exhibit 99.1.
| Item 9.01 |
Financial Statements and Exhibits.
|
|
Exhibit No.
|
Description
|
|
99.1
|
January 2026 Corporate Presentation.
|
|
104.1
|
Cover Page Interactive Data File (embedded within Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
OPUS GENETICS, INC.
|
| |
|
|
Date: January 12, 2026
|
By:
|
|
| |
Name:
|
Dr. George Magrath
|
| |
Title:
|
Chief Executive Officer
|
